Protective effects of sodium ferulate on injury in acetic acid-induced rat colitis

World Chinese Journal of Digestology

Volumn 12, Issue 1, 2004, Pages 108-111

  Liu, Shao Ping ^a   Dong, Wei Guo ^a   Luo, He Sheng ^a   Yu, Bao Ping ^a   Yu, Jie Ping ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; CYCLOOXYGENASE 2; FERULIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; MYELOPEROXIDASE; NITRIC OXIDE; PROSTAGLANDIN E2; SUPEROXIDE DISMUTASE; SYNAPTOTAGMIN; THROMBOXANE B2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; ATTENUATION; COLITIS; COLON INJURY; COLON MUCOSA; COLON MUCOSA DAMAGE INDEX; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG MECHANISM; EVALUATION; INFLAMMATION; INTESTINE PROTECTION; NONHUMAN; OCCULT BLOOD; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGLUTINATION; TISSUE PROTECTION;

EID: 1542290147     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kikuzaki H, Hisamoto M, Hirose K, Akiyama K, Taniguchi H. Antioxidant properties of ferulic acid and its related compounds. J Agric Food Chem 2002;50:2161-2168
2. Zhang ZH, Yu SZ, Li GS, Zhao BL. Influence of sodium ferulate on human netrophil-derived oxygen metabolites. Chin Pharmacol Bull 2001;17:515-517
3. Zhou JY, Fan Y, Han ZF, Wu DZ, Hu ZB. Influence of ferulic acid sodium on the enhance of endothelial permeability induced by histamine. Chin Pharmacol Bull 2000;16:664-666
4. Liu SP, Dong WD, Wu DF, Luo HS, Yu JP, Mei Q. Effects of sodium ferulate on nitric oxide synthase and cyclooxygenase in colon of colitis rats. Chin Pharmacol Bull 2003;19:571-574
5. Xie L, Yang LH, Li XH. Resarch on the pharmacologic effects of Angelica Sinensis. Res Traditional Chin Med 2000;16:56-58
6. Jiang XL, Quan QZ, Liu T, Dong XC. Recent advances in reseach of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2000;8:216-218
7. Xia B. Etiology and pathogenesis of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2001;9:245-250
8. Xu G, Tian KL, Liu GP, Zhong XJ, Tang SL, Sun YP. Clinical significance of plasma D-dimer and von Willebrand factor levels in patients with ulcer colitis. World J Gastroenterol 2002;8:575-576
9. Kirsner JB. Historical origins of current IBD concepts. World J Gastroenterol 2001;7:175-184
10. Jiang XL, Quan QZ,Wan ZK. Diagnosis, typing and therapy of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2000;8:332-334
11. Mei Q, Yu JP, Xu JM, Xiang L. The effects of melatonin on the immunological function of colitis in rats. Shijie Huaren Xiaohua Zazhi 2002;10:193-196
12. Li L, Wang ZL, Ke JT, Zhang M, Shao JF, Zhong CN. Select animal models for experimental colitis model. Shijie Huaren Xiaohua Zazhi 2001;9:584-585
13. D'Odorico A, Bortolan S, Cardin R, D'Inca R, Martines D, Ferronato A, Sturniolo GC. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol 2001;36:1289-1294
14. Krieglstein CF, Cerwinka WH, Laroux FS, Salter JW, Russell JM, Schuermann G, Grisham MB, Ross CR, Granger DN. Regulation of murine intestinal inflammation by reactive metabolites of oxygenand nitrogen: divergent roles of superoxide and nitric oxide. J Exp Med 2001;194:1207-1218
15. Huycke MM, Abrams V, Moore DR. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DAN. Carcinogenesis 2002;23:529-536
16. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, Grisham MB. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 2002;33:311-322
17. Bai AP, Shen ZX, Yu JP, Yu BP, Luo Y. Nitric oxide and the acute injury in colitis model. Shijie Huaren Xiaohua Zazhi 1999;7:900-901
18. Zhang K, Deng CS, Zhu YQ, Yang YP, Zhang YM. Signifisance of nuclear factor-κB, cyclooxygenase-2 and inducible nitric oxide synthase expression in human ulcerative colitis tissues. Shijie Huaren Xiaohua Zazhi 2002;10:575-578
19. Suzuki K, Sugimura K, Hasegawa K, Yoshida K, Suzuki A, Ishizuka K, Ohtsuka K, Honma T, Narisawa R, Asakura H. Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol 2001;36:1301-1306
20. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, Kouroumalis EA. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96:776-781
21. Cui HF, Jiang XL. Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heparin. World J Gastroenterol 1999;5:448-450
22. Carty E, MacEy M, Rampton DS. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1169-1179
23. Carty E, Macey M, McCartney SA, Rampton DS. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:807-817
24. Gil A. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother 2002;56:388-396
25. McCowen KC, Ling PR, Bistrian BR. Arachidonic acid concentrations in patients with Crohn disease. Am J Clin Nutr 2000;71:1008-1015
26. Carty E, De Brabander M, Feakins RM, Rampton DS. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 2000;46:487-492
27. Dijkstra G, Moshage H, Jansen PL. Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? Scand J Gastroenterol Suppl 2002;236:37-41
28. Li JH, Yu JP, He XF, Xu XM. Expression of NF-κB in rats with TNBS-induced ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2003;11:214-218
29. Potoka DA, Upperman JS, Nadler EP, Wong CT, Zhou X, Zhang XR, Ford HR. NF-kappaB inhibition enhances peroxynitrite-induced enterocyte apoptosis. J Surg Res 2002;106:7-14
30. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-142
31. Jobin C, Sartor RB. NF-kappaB signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflamm Bowel Dis 2000;6:206-213
32. Yamamoto Y, Gaynor RB. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med 2001;58:287-296
33. Karmeli F, Cohen P, Rachmilewitz D. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur J Gastroenterol Hepatol 2000;12:223-231
34. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS. Molecular mechanisms underiying chemopreventive activites of anti-inflammatory phytochemicals:down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001;481:243-268
35. Reifen R, Nur T, Ghebermeskel K, Zaiger G, Urizky R, Pines M. Vitamin A deficiency exacerbates inflammation in a rat model of colitis through activation of nuclear factor-kappaB and collagen formation. J Nutr 2002;132:2743-2747
36. Liu SQ, Yu JP, Luo HS, Ran ZX. Effects of Ginkgo biloba extract on expression of NF-κB in rat liver fibrosis. Shijie Huaren Xiaohua Zazhi 2002;10:922-926